Results 41 to 50 of about 35,844 (219)

Dabigatran Monitoring Was Influenced by Thrombin Time Reagent With Different Thrombin Concentrations

Clinical and Applied Thrombosis/Hemostasis, 2019
To describe the effect of dabigatran on thrombin time (TT) reagents at different concentrations of thrombin. Pooled normal plasma enriched with dabigatran was dissolved in dimethylsulfoxide (DMSO) at concentrations of 0, 20, 50, 100, 200, 300, and 500 ng/
Xiaoping Xu, Qian Liang
doaj   +1 more source

Variability in intestinal drug metabolizing enzymes and transporters in Crohn's disease and potential impact on oral drug absorption

British Journal of Clinical Pharmacology, EarlyView.
Aims The aim of study was to generate quantitative data on the abundance of drug‐metabolizing enzymes and transporters (DMETs) in inflamed and non‐inflamed Crohn's disease (CD) ileum and colon, for incorporation into physiologically based pharmacokinetic (PBPK) models, enabling prediction of oral drugs' pharmacokinetics (PK) perturbation in CD patients.
Sarah Alrubia, Brahim Achour, Zubida M. Al‐Majdoub, Amin Rostami‐Hodjegan, Jill Barber   +4 more
wiley   +1 more source

Bioactives From Brown Algae: Antioxidant, Anti‐Inflammatory, Anticancer, and Antimicrobial Potential

ChemBioEng Reviews, EarlyView.
This review explores key bioactives in brown algae and their antioxidant, anti‐inflammatory, anticancer, and antimicrobial properties. Covering studies from 2014 to 2024, it highlights their relevance in pharmaceuticals, nutraceuticals, cosmetics, and foods, while addressing challenges and future directions to unlock their full potential.
Irvin Fonseca‐Barahona, Kaveh Shahbaz, Saeid Baroutian   +2 more
wiley   +1 more source

Characteristics and outcomes in patients with atrial fibrillation receiving direct oral anticoagulants in off-label doses

BMC Cardiovascular Disorders, 2020
Background We evaluated adherence to dosing criteria for patients with atrial fibrillation (AF) taking dabigatran or rivaroxaban and the impact of off-label dosing on thromboembolic and bleeding risk.
Alexandros Briasoulis, Yubo Gao, Chakradhari Inampudi, Paulino Alvarez, Rabea Asleh, Elizabeth Chrischilles, Enrique C. Leira, Mary Vaughan-Sarrazin   +7 more
doaj   +1 more source

Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. [PDF]

, 2017
BACKGROUND: Idarucizumab, a monoclonal antibody fragment, was developed to reverse the anticoagulant effect of dabigatran. METHODS: We performed a multicenter, prospective, open-label study to determine whether 5 g of intravenous idarucizumab would be ...
Bernstein, Richard A., Dubiel, Robert, Eikelboom, John W., Glund, Stephan, Huisman, Menno V., Hylek, Elaine M., Kam, Chak-Wah, Kamphuisen, Pieter W., Kreuzer, Jörg, Levy, Jerrold H., Pollack, Charles V., Reilly, Paul A., Royle, Gordon, Sellke, Frank W., Stangier, Joachim, Steiner, Thorsten, van Ryn, Joanne, Verhamme, Peter, Wang, Bushi, Weitz, Jeffrey I., Young, Laura   +20 more
core   +1 more source

Continuation Versus Interruption of Oral Anticoagulation During TAVI: A Systematic Review and Meta‐Analysis Oral Anticoagulation Management in TAVI

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Patients undergoing transcatheter aortic valve implantation (TAVI) often require long‐term oral anticoagulation (OAC), but it is unclear whether to continue or interrupt OAC during the procedure. This meta‐analysis compares clinical outcomes of continuing versus interrupting OAC during TAVI.
Jefferson Manoel Borges Martins, Rafael dos Santos Borges, Giovanni Gosch Berton, Paula Larissa Ferreira Vieira, Pedro Antônio Machado Gomes de Sousa, Ana Livia Chaves Vieira, Christian Ken Fukunaga, Vanessa Karlinski Vizentin, Esthefani Monique Rodrigues Macedo, Camila Mota Guida   +9 more
wiley   +1 more source

Coagulopathy and Extremely Elevated PT/INR after Dabigatran Etexilate Use in a Patient with End-Stage Renal Disease

Case Reports in Medicine, 2013
Introduction. Dabigatran is an oral direct thrombin inhibitor which has been approved for prophylaxis of stroke in patients with atrial fibrillation. The use of dabigatran etexilate increased rapidly due to many benefits.
Joonseok Kim, Mrinal Yadava, In Chul An, Abrar Sayeed, Heather S. Laird-Fick, Venu Gourineni, George S. Abela   +6 more
doaj   +1 more source

Cost-Utility Analysis of Venous Thromboembolism Prophylaxis Strategies for People Undergoing Elective Total Hip and Total Knee Replacement Surgeries in the English National Health Service [PDF]

, 2018
Background: Major orthopedic surgery, such as elective total hip replacement (eTHR) and elective total knee replacement (eTKR), are associated with a higher risk of venous thromboembolism (VTE) than other surgical procedures.
Anderson, Annemans, Arya, Barco, Bischof, Bjorvatn, Botteman, Braidy, Brockbank, Capri, Caprini, Cohoon, Curtis, Dahl, Dahl, Davies, Diamantopoulos, Dranitsaris, Dranitsaris, Ende-Verhaar, Gomez-Outes, Gordois, Gould, Haentjens, Hamidi, Hauck, Heit, Husereau, Jameson, Jameson, Kahn, Kapoor, Lundkvist, McCullagh, McCullagh, McDonald, Migliaccio-Walle, Postma, Quinlan, Reeves, Revankar, Riemsma, Roberts, Ryttberg, Sterne, Stevenson, Wade, Wang, Warwick, White, Wille-Jørgensen, Wolowacz, Wolowacz, Zindel   +53 more
core   +3 more sources

Impact of Age and Factor Xa Inhibitor Concentrations on Bleeding Risk in Patients with Atrial Fibrillation

Clinical Pharmacology &Therapeutics, EarlyView.
This study aimed to analyze differences in the exposure‐response relationship for factor Xa inhibitors (FXaI) between patients aged ≥ 80 and < 80 years. Patients with atrial fibrillation (AF) taking rivaroxaban, apixaban, or edoxaban were enrolled, and a single steady‐state trough concentration was measured.
Shin‐Yi Lin, Yen‐Bing Liu, Li‐Ting Ho, Ching‐Hua Kuo, Yu‐Fong Peng, Chih‐Fen Huang, Sung‐Chun Tang, Jiann‐Shing Jeng   +7 more
wiley   +1 more source

Clinical performance of the atrial fibrillation in the Russian population depending on the antithrombotic therapy: findings from the GLORIA-AF registry phase 2

Российский кардиологический журнал, 2020
Aim. To analyze clinical characteristics of patients with nonvalvular atrial fibrillation (AF) in the Russian population, enrolled in the GLORIA-AF registry phase 2, depending on the antithrombotic therapy received, and to assess the potential for ...
E. V. Shlyakhto, S. V. Villevalde, A. V. Ezhov, S. A. Zenin, N. A. Koziolova, O. Yu. Korennova, T. N. Novikova, K. V. Protasov, G. A. Chumakova, C. Teutsch, S. Lu, G. Y. H. Lip, M. V. Huisman   +12 more
doaj   +1 more source